The novel SARS-CoV-2 has rapidly develop into a world pandemic for the reason that first reported case in December 2019, with the virus infecting tens of millions of individuals to this point. The spike (S) protein of the SARS-CoV-2 virus performs a key function in binding to angiotensin-converting enzyme 2 (ACE2), a number cell receptor for SARS-CoV-2. S proteins which are expressed on the cell membrane can provoke receptor-dependent syncytia formation that’s related to intensive tissue harm. Formation of syncytia have been beforehand noticed in cells contaminated with varied different viruses (e.g., HIV, Ebola, Influenza, and Herpesviruses).
Nevertheless, this phenomenon isn’t properly documented and the mechanisms regulating the formation of those syncytia by SARS-CoV-2 aren’t totally understood. On this research, we investigated the chance that cell fusion occasions mediated by the S protein of SARS-CoV-2 and ACE2 interplay can happen in several human cell strains that mimic totally different tissue origins. These cell strains have been stably transduced with both wild-type (WT-S) S protein or a mutated variant the place the ER-retention motif was eliminated (Δ19-S), or human ACE2 vectors.
Totally different co-culture mixtures of spike-expressing 293T, A549, Ok562, and SK-Hep1 cells with hACE2-expressing cells revealed cell hybrid fusion. Nevertheless, solely sure cells expressing S protein can kind syncytial buildings as this phenomenon can’t be noticed in all co-culture mixtures. Thus, SARS-CoV-2 mediated cell-cell fusion represents a cell type-dependent course of which could depend on a distinct set of parameters. Just lately, the Δ19-S variant is being broadly used to extend SARS-CoV-2 pseudovirus manufacturing for in vitro assays.
Comparability of cell fusion occurring by way of Δ19-S expressing cells exhibits faulty nuclear fusion and syncytia formation in comparison with WT-S. This distinction between the Δ19-S variant and WT-S protein might have downstream implications for research that make the most of pseudovirus-based entry assays. Moreover, this research counsel that spike protein expressed by vaccines might have an effect on totally different ACE2-expressing host cells after SARS-CoV-2 vaccine administration. The long-term results of those vaccines must be monitored rigorously.
Molecular and Mobile Mechanisms of Respiratory Syncytial Viral An infection: Utilizing Murine Fashions to Perceive Human Pathology
Respiratory syncytial virus (RSV) causes extreme pathology of the decrease respiratory tract in infants, immunocompromised individuals, and aged. Regardless of a long time of analysis, there isn’t any licensed vaccine in opposition to RSV, and plenty of therapeutic medicine are nonetheless underneath improvement. Detailed understanding of molecular and mobile mechanisms of the RSV an infection pathology can speed up the event of efficacious therapy. Present research on the RSV pathogenesis are primarily based on the evaluation of biopsies from the contaminated sufferers; nonetheless deeper understanding of molecular and mobile mechanisms of the RSV pathology could possibly be achieved utilizing animal fashions.
Mice are essentially the most typically used mannequin for RSV an infection as a result of they exhibit manifestations much like these noticed in people (bronchial obstruction, mucous hypersecretion, and pulmonary irritation mediated by lymphocytes, macrophages, and neutrophils). Moreover, using mice is economically possible, and plenty of molecular instruments can be found for learning RSV an infection pathogenesis on the molecular and mobile ranges. This evaluation summarizes new information on the pathogenesis of RSV an infection obtained in mouse fashions, which demonstrated the function of T cells in each the antiviral protection and the event of lung immunopathology.
T cells not solely get rid of the contaminated cells, but additionally produce vital quantities of the proinflammatory cytokines TNFα and IFNγ. Just lately, a brand new subset of tissue-resident reminiscence T cells (TRM) was recognized that present a powerful antiviral protection with out induction of lung immunopathology. These cells accumulate within the lungs after native somewhat than systemic administration of RSV antigens, which suggests new approaches to vaccination. The research in mouse fashions have revealed a minor function of interferons within the anti-RSV safety, as RSV possesses mechanisms to flee the antiviral motion of kind I and III interferons, which can clarify the low efficacy of interferon-containing medicine.
Utilizing knockout mice, a major breakthrough has been achieved in understanding the function of many pro-inflammatory cytokines in lung immunopathology. It was discovered that along with TNFα and IFNγ, the cytokines IL-4, IL-5, IL-13, IL-17A, IL-33, and TSLP mediate the main manifestations of the RSV pathogenesis, equivalent to bronchial obstruction, mucus hyperproduction, and lung infiltration by pro-inflammatory cells, whereas IL-6, IL-10, and IL-27 exhibit the anti-inflammatory impact. Regardless of vital variations between the mouse and human immune methods, mouse fashions have made a major contribution to the understanding of molecular and mobile mechanisms of the pathology of human RSV an infection.
Competitors between RSV and influenza: Limits of modelling inference from surveillance information
Respiratory Syncytial Virus (RSV) and Influenza trigger a big burden of illness. Proof of their interplay by way of short-term cross-protection implies that prevention of 1 may inadvertently result in a rise within the burden of the opposite. Nevertheless, proof for the general public well being influence of such interplay is sparse and largely derives from ecological analyses of peak shifts in surveillance information. To check the robustness of estimates of interplay parameters between RSV and Influenza from surveillance information we carried out a simulation and back-inference research.
pPACK-SPIKE Combo Kit, includes Cat# CVD19-500A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-520A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE D614G Combo Kit, includes Cat# CVD19-530A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-550A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE N501Y Combo Kit, includes Cat# CVD19-560A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-575A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE Alpha Combo Kit, includes Cat# CVD19-590A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-599A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE Gamma Combo Kit, includes Cat# CVD19-630A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-639A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE Beta Combo Kit, includes Cat# CVD19-640A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-649A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE Delta Combo Kit, includes Cat# CVD19-650A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-659A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE Omicron Combo Kit, includes Cat# CVD19-660A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-669A-KIT |
SBI |
1 kit |
EUR 1162 |
pPACK-SPIKE B.1.429 Combo Kit, includes Cat# CVD19-610A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-619A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE B.1.525 Combo Kit, includes Cat# CVD19-620A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-629A-KIT |
SBI |
1 kit |
EUR 1141 |
Human Glucose concentration-Glucose concentration- ELISA Kit |
QY-E05365 |
Qayee Biotechnology |
96T |
EUR 400 |
pPACK-SPIKE B.1.351 RBD Mutations Combo Kit, includes Cat# CVD19-580A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-589A-KIT |
SBI |
1 kit |
EUR 1141 |
pPACK-SPIKE B.1.351 S1 Mutations Combo Kit, includes Cat# CVD19-600A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) |
CVD19-609A-KIT |
SBI |
1 kit |
EUR 1141 |
Gas concentration agent |
nBIONIX-A07 |
Bulldog Bio |
20 |
EUR 138 |
ETHANOL, 70% CONCENTRATION |
IB15727 |
IBI Scientific |
10L |
EUR 210.13 |
Description: BOX W/SPIGOT (HAZ) |
Lentivirus Concentrator |
LV-CONC |
GenTarget |
one kit |
EUR 276.5 |
Description: lentivirus concentration kit |
Denhardt's solution, 100x Concentrate |
D0062 |
Bio Basic |
25ml |
EUR 82.97 |
|
Wash Solution Concentrate (HPE) |
DS0024-125ML |
EWC Diagnostics |
1 unit |
EUR 141.01 |
Description: Wash Solution Concentrate (HPE) |
Wash Solution Concentrate (HPE) |
DS0024-250ML |
EWC Diagnostics |
1 unit |
EUR 280.84 |
Description: Wash Solution Concentrate (HPE) |
Prewash Solution Concentrate (PW) |
DS0011-400ML |
EWC Diagnostics |
1 unit |
EUR 240.82 |
Description: Prewash Solution Concentrate (PW) |
Minimal Inhibitory Concentration Kit |
K195-2500 |
Biovision |
each |
EUR 836.4 |
Minimal Inhibitory Concentration Kit |
K195-500 |
Biovision |
each |
EUR 574.8 |
X-Gal Solution, 40 mg/ml concentrate |
X0321-005 |
GenDepot |
5X1ml |
EUR 45 |
X-Gal Solution, 40 mg/ml concentrate |
X0321-020 |
GenDepot |
20ml |
EUR 70 |
AvaI -HC unit: 330, High Concentration |
YRAVA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
SacI -HC unit: 1500, High Concentration |
YRSAC1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Concentrating Solution for Sirius Red Total Collagen Detection Other |
90626 |
Chondrex |
50 ml |
EUR 14 |
Description: Concentrating Solution for Sirius Red Total Collagen Detection Kit |
Kpn I -HC unit: 5000, High Concentration |
YRKPN1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Msp I -HC unit: 1400, High Concentration |
YRMSP1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Nco I -HC unit: 400, High Concentration |
YRNCO1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Pst I -HC unit: 12000, High Concentration |
YRPST1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Pvu II -HC unit: 2000, High Concentration |
YRPVU2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Rsa I -HC unit: 800, High Concentration |
YRRSA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Sal I -HC unit: 2200, High Concentration |
YRSAL1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Sma I -HC unit: 1500, High Concentration |
YRSMA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Taq I -HC unit: 410, High Concentration |
YRTAQ1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Xba I -HC unit: 3000, High Concentration |
YRXBA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Xho I -HC unit: 5000, High Concentration |
YRXHO1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hi-SYBr Master Mix (Concentration 2X) |
MBT074-0.5ML |
EWC Diagnostics |
1 unit |
EUR 54.43 |
Description: Hi-SYBr Master Mix (Concentration 2X) |
Hi-SYBr Master Mix (Concentration 2X) |
MBT074-1ML |
EWC Diagnostics |
1 unit |
EUR 104.64 |
Description: Hi-SYBr Master Mix (Concentration 2X) |
Hi-SYBr Master Mix (Concentration 2X) |
MBT074-5ML |
EWC Diagnostics |
1 unit |
EUR 418.52 |
Description: Hi-SYBr Master Mix (Concentration 2X) |
Dra I-HC unit: 3500, High Concentration |
YRDRA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EcoR I -HC unit: 12000, High Concentration |
YRECOR1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EF1a-(Red-Luciferase) Lentivirus
(Zeocin), Concentrated Lentivirus |
LVP1304-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
Description: concentrated lentivirus in PBS express Red-Luciferease under EF1a promoter, containing Zeocin selection. |
BamH I-HC unit: 12000, High Concentration |
YRBAMH1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Bgl II-HC unit: 2500, High Concentration |
YRBGL2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EcoR V-HC unit: 2000, High Concentration |
YRECOR5-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hind III -HC unit: 12000, High Concentration |
YRHIND3-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hinf I-HC unit: 2000, High Concentration |
YRHINF1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
ViaCheck™ Concentration Control (0.5 × 106) |
VC50N-20 |
Polysciences Europe GmbH |
20 mL |
EUR 247.32 |
Description: HS Code : 38220000 |
ViaCheck Concentration Control 1 x 106 |
VC60N-20 |
Bangs Laboratories |
20 ml |
EUR 251.33 |
Description: ViaCheck Concentration Control 1 x 106 mimic the characteristics of live and dead cells in the trypan blue dye exclusion method and may be used to support validation and QC of image-based cell viability analyzers |
ViaCheck Concentration Control 4 x 106 |
VC70N-20 |
Bangs Laboratories |
20 ml |
EUR 367.48 |
Description: ViaCheck Concentration Control 4 x 106 mimic the characteristics of live and dead cells in the trypan blue dye exclusion method and may be used to support validation and QC of image-based cell viability analyzers |
ViaCheck Concentration Control 8 x 106 |
VC80N-20 |
Bangs Laboratories |
20 ml |
EUR 410.53 |
Description: ViaCheck Concentration Control 8 x 106 mimic the characteristics of live and dead cells in the trypan blue dye exclusion method and may be used to support validation and QC of image-based cell viability analyzers |
Cas9 Nuclease Protein (High Concentration) |
K108 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 80 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
UPCK™ Urine Protein Concentration Kit |
UPCK-25 |
Biotech Support Group |
25 preps |
EUR 1143.6 |
Description: Urine Protein Enrichment Kit |
BssH II-HC unit: 200, High Concentration |
YRBSSH2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
BstE II-HC unit: 1300, High Concentration |
YRBSTE2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EcoT38 I -HC unit: 900, High Concentration |
YRECOT38-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hae III-HC unit: 3400, High Concentration |
YRHAE3-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hinc II-HC unit: 500, High Concentration |
YRHINC2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EF1a-(Red-Luciferase) Lentivirus
(Neomycin), Concentrated Lentivirus |
LVP1234-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
Description: concentrated lentivirus in PBS express Red-Luciferease under EF1a promoter, containing Neomycin selection. |
saCas9 Nuclease Protein (High Concentration) |
K144 |
ABM |
32.5 µg (250pmol) Volume: 25µL |
EUR 155 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). |
EF1a-(Red-Luciferase) Lentivirus
(Hygromycin), Concentrated Lentivirus |
LVP1305-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
Description: concentrated lentivirus in PBS express Red-Luciferease under EF1a promoter, containing Hygromycin selection. |
EF1a-(Red-Luciferase) Lentivirus
(Puromycin), Concentrated Lentivirus |
LVP475-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
Description: concentrated lentivirus in PBS express Red-Luciferease under EF1a promoter, containing Puromycin selection. |
BCA Protein concentration determination kit |
BC016-500ml |
ELK Biotech |
500ml |
EUR 110 |
h LDOC1 (HA), Concentrated Lentivirus |
LVP1132-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
Description: Premade lentivirus over-express human LDOC1 gene with N-term HA tag. It contains a RFP_Blasticidin fusion dual marker. |
Cas9 Null Mutant Protein (High Concentration) |
K140 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type Cas9 (D10A and H840A). Such a Cas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, unlike Cas9 Nuclease and Cas9 Nickase, where permanent gene disruption can be achieved, the Cas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
EF1a-(Red-Luciferase) Lentivirus
(Blasticidin), Concentrated Lentivirus |
LVP1232-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
Description: concentrated lentivirus in PBS express Red-Luciferease under EF1a promoter, containing Blasticidin selection. |
Cas9 Nuclease NLS Protein (High Concentration) |
K130 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 80 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 Nuclease NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
Cas9 Nickase D10A Protein (High Concentration) |
K132 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To counteract off-target mutagenic effects of this system, the Cas9 Nickase D10A was developed with a D10A mutation in its RuvC1 nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
h NEUROG2 Expression Lentivirus, concentrated |
LVP658-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
Description: Concentrated lentivirus express human target: NEUROG2 (neurogenin 2), containing RFP-Blasticidin dual selection |
dNTP SET, Concentration: 100mM, 4x1ml
set of dNTP consisting 4 separate tubes (4x1ml) each with 100mM concentration of dATP, dGTP, dCTP, and dTTP. |
2013SET |
ACTGene |
each |
EUR 361.42 |
|
Myoglobin Concentration ELISA Quantitation Kit |
GWB-E1E945 |
GenWay Biotech |
ELISA_Kits |
Ask for price |
m Plaur (CD87), Concentrated Lentivirus |
LVP1400-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
Description: lentivirus express mouse target: Plaur (CD87), containing a RFP-Blasticidin dual selection marker. |
h IL1R1 (6His), Concentrated Lentivirus |
LVP1133-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
Description: Premade lentivirus over-express human IL1R1 gene with C-term 6His tag. It contains a RFP_Blasticidin fusion dual marker. |
Cas9 Nickase H840A Protein (High Concentration) |
K136 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To improve the off-target mutagenic effects of this system, the Cas9 Nickase H840A Protein was developed with a H840A mutation in its HNH-like nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
saCas9 Null Mutant Protein (High Concentration) |
K146 |
ABM |
32.5 µg (250pmol) Volume: 25µL |
EUR 155 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The saCas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type saCas9. Such a saCas9 protein retains its ability to bind to genomic DNA through sgRNA:genomic DNA base pairing, however, the saCas9 Null Mutant does not induce cleavage. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). |
GFP (CMV, No antibiotics) Lentivirus, Concentrated |
LVP1334-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
Description: Concentrated Lentivirus express GFP under CMV promoter (Does not contain any antibioic selection.) |
RFP (CMV, No antibiotics) Lentivirus, Concentrated |
LVP1336-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
Description: Concentrated Lentivirus express GFP under CMV promoter (Does not contain any antibioic selection.) |
Taq DNA Polymerase (recombinant), Low Concentration - 500 U |
THEP0404 |
Westburg |
each |
EUR 189.66 |
AAVancedTM Concentration Reagent (100 ml aliquot) |
AAV100A-1 |
SBI |
100 ml |
EUR 462 |
AAVancedTM Concentration Reagent (250 ml aliquot) |
AAV110A-1 |
SBI |
250 ml |
EUR 928 |
asCpf1 Nuclease NLS Protein (High Concentration) |
K088 |
ABM |
38 μg (250 pmol) Volume: 25µL |
EUR 75 |
Description: Using Cpf1 (a.k.a. Cas12a) in your CRISPR experiment offers several advantages over other CRISPR-associated nucleases.; - Due to the T-rich PAM sequence (TTTN), Cpf1 enables editing in regions unable to be targeted by Cas9.
- Cpf1 can be used with a shorter guide RNA (called crRNA) than Cas9.
- Cpf1 creates a staggered cut in dsDNA instead of a blunt cut.
- Cpf1 cuts distal to the PAM sequence, which may allow for multiple rounds of cleavage.
asCpf1 is from the bacteria Acidaminococcus. This protein contains a SV40 T antigen nuclear localization signal (NLS) on the N-terminus of the protein. If the cut caused by asCpf1 is repaired by non-homologous end joining (NHEJ), an indel may be formed that disrupts the open reading frame of the targeted gene, leading to gene knockout. Alternatively, by supplying a repair template, a sequence can be knocked in at the cleavage site via homology directed repair (HDR).
|
saCas9 Nuclease NLS Protein (High Concentration) |
K089 |
ABM |
6.5 µg (50pmol) Volume: 50µL |
EUR 55 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). saCas9 Nuclease NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
fnCpf1 Nuclease NLS Protein (High Concentration) |
K187 |
ABM |
380 μg (2.5 nmol) Volume: 250µL |
EUR 365 |
Description: Using Cpf1 (a.k.a. Cas12a) in your CRISPR experiment offers several advantages over other CRISPR-associated nucleases.; - Due to the T-rich PAM sequence (TTTN), Cpf1 enables editing in regions unable to be targeted by Cas9.
- Cpf1 can be used with a shorter guide RNA (called crRNA) than Cas9.
- Cpf1 creates a staggered cut in dsDNA instead of a blunt cut.
- Cpf1 cuts distal to the PAM sequence, which may allow for multiple rounds of cleavage.
fnCpf1 is from the bacteria Francisella novicida. This protein contains a SV40 T antigen nuclear localization signal (NLS) on the N-terminus of the protein. If the cut caused by fnCpf1 is repaired by non-homologous end joining (NHEJ), an indel may be formed that disrupts the open reading frame of the targeted gene, leading to gene knockout. Alternatively, by supplying a repair template, a sequence can be knocked in at the cleavage site via homology directed repair (HDR).
|
asCpf1 Nuclease NLS Protein (High Concentration) |
K188 |
ABM |
380 μg (2.5 nmol) Volume: 250µL |
EUR 365 |
Description: Using Cpf1 (a.k.a. Cas12a) in your CRISPR experiment offers several advantages over other CRISPR-associated nucleases. ; - Due to the T-rich PAM sequence (TTTN), Cpf1 enables editing in regions unable to be targeted by Cas9.
- Cpf1 can be used with a shorter guide RNA (called crRNA) than Cas9.
- Cpf1 creates a staggered cut in dsDNA instead of a blunt cut.
- Cpf1 cuts distal to the PAM sequence, which may allow for multiple rounds of cleavage.
asCpf1 is from the bacteria Acidaminococcus. This protein contains a SV40 T antigen nuclear localization signal (NLS) on the N-terminus of the protein. If the cut caused by asCpf1 is repaired by non-homologous end joining (NHEJ), an indel may be formed that disrupts the open reading frame of the targeted gene, leading to gene knockout. Alternatively, by supplying a repair template, a sequence can be knocked in at the cleavage site via homology directed repair (HDR).
|
saCas9 Nuclease NLS Protein (High Concentration) |
K189 |
ABM |
32.5 µg (250pmol) Volume: 50µL |
EUR 155 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). saCas9 Nuclease NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
We developed a two-pathogen interplay mannequin, parameterised to simulate RSV and Influenza epidemiology within the UK. Utilizing the an infection mannequin together with a surveillance-like stochastic remark course of we generated a variety of doable RSV and Influenza trajectories after which used Markov Chain Monte Carlo (MCMC) strategies to back-infer parameters together with these describing competitors.